ES2309383T3 - Pirrolil tiazoles y su empleo como agonistas inversos de receptores cb1. - Google Patents

Pirrolil tiazoles y su empleo como agonistas inversos de receptores cb1. Download PDF

Info

Publication number
ES2309383T3
ES2309383T3 ES03789381T ES03789381T ES2309383T3 ES 2309383 T3 ES2309383 T3 ES 2309383T3 ES 03789381 T ES03789381 T ES 03789381T ES 03789381 T ES03789381 T ES 03789381T ES 2309383 T3 ES2309383 T3 ES 2309383T3
Authority
ES
Spain
Prior art keywords
lower alkyl
lower alkoxy
fluorinated
amino
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03789381T
Other languages
English (en)
Inventor
Wolfgang Guba
Wolfgang Haap
Hans Peter Marty
Robert Narquizian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2309383T3 publication Critical patent/ES2309383T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Compuestos de la fórmula (I) (Ver fórmula) en la que R 1 es hidrógeno o alquilo inferior; R 2 es hidrógeno, alquilo inferior, alquenilo inferior, alcoxi inferior-alquilo inferior, (alcoxi inferior)carbonilamino, -(CH2)m-R 2a o -NHC(O)-R 2a ; o R 1 y R 2 junto con el átomo de nitrógeno al que están unidos forman un anillo heterocíclico saturado de 5 ó 6 eslabones que contiene eventualmente uno o dos heteroátomos adicionales elegidos con independencia entre sí entre nitrógeno, oxígeno y azufre, dicho anillo heterocíclico está eventualmente mono-, di- o trisustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, amino, (alquilo inferior)amino, alquilo inferior fluorado o alcoxi inferior fluorado; R 2a es cicloalquilo, eventualmente mono-, di-, tri- o tetrasustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, alquilo inferior fluorado o alcoxi inferior fluorado; cicloalquenilo, eventualmente mono-, di- o trisustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, alquilo inferior fluorado o alcoxi inferior fluorado; un anillo heterocíclico saturado monovalente de 5 ó 6 eslabones que contiene de uno a tres heteroátomos elegidos con independencia entre sí entre nitrógeno, oxígeno y azufre, dicho anillo heterocíclico está eventualmente mono-, di- o trisustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, amino, (alquilo inferior)amino, alquilo inferior fluorado o alcoxi inferior fluorado; un anillo heteroaromático monovalente de 5 ó 6 eslabones que contiene de uno a tres heteroátomos elegidos con independencia entre sí entre nitrógeno, oxígeno y azufre, dicho anillo heteroaromático está eventualmente mono-, di- o trisustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, halógeno, amino, (alquilo inferior)amino; o fenilo, que puede estar eventualmente mono-, di- o trisustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, halógeno, (alquilo inferior)amino, alquilo inferior halogenado, alcoxi inferior halogenado o nitro; R 3 es alquilo inferior, alquenilo inferior, alcoxi inferior-alquilo inferior, di-fenil-alquilo inferior o -(CH2)n-R 3a ; R 3a es cicloalquilo, que puede estar eventualmente fusionado con un anillo fenilo; o cicloalquilo que puede estar eventualmente mono-, di- o trisustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, alquilo inferior fluorado o alcoxi inferior fluorado; cicloalquenilo, que puede estar eventualmente mono-, di- o trisustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, alquilo inferior fluorado o alcoxi inferior fluorado; un anillo heterocíclico saturado monovalente de 5 ó 6 eslabones que contiene de uno a tres heteroátomos elegidos con independencia entre sí entre nitrógeno, oxígeno y azufre, dicho anillo heterocíclico está eventualmente mono-, di- o trisustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, amino, (alquilo inferior)amino, alquilo inferior fluorado o alcoxi inferior fluorado; un anillo heteroaromático monovalente de 5 ó 6 eslabones que contiene de uno a tres heteroátomos elegidos con independencia entre sí entre nitrógeno, oxígeno y azufre, dicho anillo heteroaromático está eventualmente mono-, di- o trisustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, halógeno, amino o (alquilo inferior)amino; o fenilo, que puede estar eventualmente mono-, di- o trisustituido, con independencia entre sí, por hidroxi, alquilo inferior, alcoxi inferior, halógeno, (alquilo inferior)amino, alquilo inferior halogenado, alcoxi inferior halogenado o nitro; R 4 es...
ES03789381T 2003-01-02 2003-12-22 Pirrolil tiazoles y su empleo como agonistas inversos de receptores cb1. Expired - Lifetime ES2309383T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03000002 2003-01-02

Publications (1)

Publication Number Publication Date
ES2309383T3 true ES2309383T3 (es) 2008-12-16

Family

ID=32695581

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03789381T Expired - Lifetime ES2309383T3 (es) 2003-01-02 2003-12-22 Pirrolil tiazoles y su empleo como agonistas inversos de receptores cb1.

Country Status (18)

Country Link
US (1) US7135488B2 (es)
EP (1) EP1583762B1 (es)
JP (1) JP4271660B2 (es)
KR (1) KR100674769B1 (es)
CN (1) CN100360527C (es)
AR (1) AR042690A1 (es)
AT (1) ATE400571T1 (es)
AU (1) AU2003293968A1 (es)
BR (1) BR0317931A (es)
CA (1) CA2511905A1 (es)
CL (1) CL2003002769A1 (es)
DE (1) DE60322114D1 (es)
ES (1) ES2309383T3 (es)
MX (1) MXPA05007115A (es)
PL (1) PL378244A1 (es)
RU (1) RU2330035C2 (es)
TW (1) TW200412344A (es)
WO (1) WO2004060888A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007114A (es) 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.
ATE386725T1 (de) * 2003-10-24 2008-03-15 Glaxo Group Ltd Heterocyclylverbindungen
US8026237B2 (en) * 2004-07-30 2011-09-27 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
BRPI0706623A2 (pt) * 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
BRPI0806498A2 (pt) 2007-01-04 2014-04-22 Prosidion Ltd Agonistas gpcr piperidina
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
EP2548874A3 (en) * 2007-06-28 2013-05-15 Intervet International B.V. Substituted piperazines as CB1 antagonists
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
KR100954316B1 (ko) * 2007-12-05 2010-04-21 한국화학연구원 신규한 1-[1-(3,4-디알콕시벤질)-1ｈ-피롤 화합물, 이의제조방법 및 이를 포함하는 천식 및 만성폐쇄성 폐질환을포함한 염증관련 질환, 관절염, 아토피 피부염, 암 및뇌질환의 치료 및 예방을 위한 약제학적 조성물
AU2010313622B2 (en) 2009-11-02 2014-08-14 Ahr Pharmaceuticals, Inc. ITE for cancer intervention and eradication
US10632106B2 (en) 2009-11-02 2020-04-28 Ariagen, Inc. Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
PT2718290T (pt) * 2011-06-07 2016-07-14 Clevexel Pharma Composições e métodos para modular uma quinase
US9815851B2 (en) 2011-12-02 2017-11-14 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
EP3191481B1 (en) * 2014-09-12 2020-11-25 Ariagen, Inc. Efficient and scalable systhesis of 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester and its structural analogs
CN113480530A (zh) 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
KR20200089718A (ko) 2017-11-20 2020-07-27 아리아젠, 인크. 인돌 화합물 및 이의 용도
CA3137027A1 (en) 2019-04-15 2020-10-22 Ariagen, Inc. Chiral indole compounds and their use
CN113069451B (zh) * 2021-04-02 2022-08-09 苏州大学 一种吡咯-2-磺酰胺化合物的制备方法及其在制备抗肿瘤药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
IL113112A (en) * 1994-03-28 2000-06-01 Nissan Chemical Ind Ltd Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
JP2004500401A (ja) 2000-03-23 2004-01-08 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Ｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体
FR2814678B1 (fr) 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
MXPA05007114A (es) * 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.

Also Published As

Publication number Publication date
AU2003293968A1 (en) 2004-07-29
CL2003002769A1 (es) 2005-01-07
EP1583762B1 (en) 2008-07-09
US20040147572A1 (en) 2004-07-29
JP2006513226A (ja) 2006-04-20
WO2004060888A1 (en) 2004-07-22
CA2511905A1 (en) 2004-07-22
RU2005124359A (ru) 2006-05-27
AR042690A1 (es) 2005-06-29
PL378244A1 (pl) 2006-03-20
MXPA05007115A (es) 2005-11-16
EP1583762A1 (en) 2005-10-12
KR20050092381A (ko) 2005-09-21
TW200412344A (en) 2004-07-16
RU2330035C2 (ru) 2008-07-27
JP4271660B2 (ja) 2009-06-03
ATE400571T1 (de) 2008-07-15
CN100360527C (zh) 2008-01-09
CN1735611A (zh) 2006-02-15
BR0317931A (pt) 2005-11-29
KR100674769B1 (ko) 2007-02-28
DE60322114D1 (de) 2008-08-21
US7135488B2 (en) 2006-11-14

Similar Documents

Publication Publication Date Title
ECSP045276A (es) O-ciclopropil-carboxanilidas y su uso como fungicidas
CO5050295A1 (es) Activadores trans olefinicos de la glucokinasa
AR042691A1 (es) Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas.
PE20081344A1 (es) Inhibidores del virus de la hepatitis c
EA200800737A1 (ru) Поперечно связанные соединения циклических аминов и средства для борьбы с вредителями
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
AR055144A1 (es) Inhibidor de secrecion acida
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
AR075084A1 (es) Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
CO6160231A2 (es) Compuestos de isoindolina 5-substituidos
MX2009006286A (es) Composiciones plaguicidas.
ECSP088431A (es) Derivados de pirazolo
CO5640155A2 (es) Derivados de pirido[2,1-a]isoquinolina como inhibidores de la dpp-iv
ECSP099638A (es) Nuevo compuesto de adenina
PE20001464A1 (es) Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos
AR074909A1 (es) Compuestos de imina para combatir plagas de invertebrados
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
NO20071476L (no) Antidiuretiske midler.
PE20131380A1 (es) Agente de control de plagas
TW200615267A (en) New bicyclic antibiotics
ES2175804T3 (es) Nuevas pirimidin-4-ona y primidin-4-tiona como fungicida.
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
AR044695A1 (es) Derivados de azolidina, utiles como herbicidas.
PE20080889A1 (es) Aminometil-4-imidazoles
CO6150147A2 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii